CA2990222A1 — Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Assigned to Exelixis Inc · Expires 2017-01-05 · 9y expired
What this patent protects
This disclosure relates to the provision of pharmaceutically useful forms of crystalline fumarate salts of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)pheny1] [3-hydroxy-3-(piperidin-2-y1) azetidin-l-y1]-methanone having the formula: The disclosure also relates to pharmace…
USPTO Abstract
This disclosure relates to the provision of pharmaceutically useful forms of crystalline fumarate salts of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)pheny1] [3-hydroxy-3-(piperidin-2-y1) azetidin-l-y1]-methanone having the formula: The disclosure also relates to pharmaceutical compositions comprising the crystalline fumarate salt of (S)43,4-difluoro-2-(2-fluoro-4- iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-y azetidin-1-yll-methanone. The disclosure also relates to methods of treating cancers comprising administering to a patient in need thereof the crystalline fumarate salt of (S)- [3,4- difluor o-2-(2-flu oro- 4- iodopheny lamin o)pheny 1] [3 -hydroxy -3- (p iperid in- 2-y 1) aze tidin- 1-y 1]-methanone.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.